Compare · ILMN vs SPNE
ILMN vs SPNE
Side-by-side comparison of Illumina Inc. (ILMN) and SeaSpine Holdings Corporation (SPNE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMN and SPNE operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN carries a market cap of $31.68B.
- ILMN has hit the wire 15 times in the past 4 weeks while SPNE has been quiet.
- ILMN has more recent analyst coverage (25 ratings vs 5 for SPNE).
- Company
- Illumina Inc.
- SeaSpine Holdings Corporation
- Price
- -
- -
- Market cap
- $31.68B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 15
- 0
- Recent ratings
- 25
- 5
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
SeaSpine Holdings Corporation
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. Its orthobiologics products include demineralized bone matrices (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and demineralized bone matrices. Its spinal implant portfolio comprises products for spinal decompression, alignment, and stabilization that are used to facilitate fusion in degenerative, minimally invasive surgery, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical spine. The company has development and licensing agreement with restor3d, Inc. and 7D Surgical, Inc. to develop 3D-printed interbody devices. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.
Latest ILMN
- Director Meister Keith A. sold $61,093,041 worth of shares (280,091 units at $218.12) (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $58,142 worth of shares (267 units at $217.76), decreasing direct ownership by 2% to 14,029 units (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 360 shares, decreasing direct ownership by 0.88% to 40,567 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D covered exercise/tax liability with 150 shares, decreasing direct ownership by 1% to 14,296 units (SEC Form 4)
- SVP, Chief People Officer Leckman Patricia covered exercise/tax liability with 208 shares, decreasing direct ownership by 0.98% to 21,120 units (SEC Form 4)
- Chief of Global Operations Pegels Kevin Carl covered exercise/tax liability with 604 shares, decreasing direct ownership by 2% to 28,434 units (SEC Form 4)
- Illumina advances MRD research portfolio with ultrasensitive duplex sequencing technology
- Director Meister Keith A. sold $66,560,212 worth of shares (281,433 units at $236.50) (SEC Form 4)
- Illumina selected to help bring precision medicine into everyday healthcare in Singapore
- SEC Form 10-Q filed by Illumina Inc.
Latest SPNE
- SEC Form CT ORDER filed by SeaSpine Holdings Corporation
- SEC Form SC 13G/A filed by SeaSpine Holdings Corporation (Amendment)
- SEC Form 15-12G filed by SeaSpine Holdings Corporation
- SEC Form EFFECT filed by SeaSpine Holdings Corporation
- SEC Form EFFECT filed by SeaSpine Holdings Corporation
- SEC Form EFFECT filed by SeaSpine Holdings Corporation
- SEC Form 4: Stephenson Kirtley C. returned 138,340 shares to the company, closing all direct ownership in the company
- SEC Form 4: Steinway Angela returned 23,725 shares to the company, closing all direct ownership in the company
- SEC Form 4: Maniar Shweta returned 23,993 shares to the company, closing all direct ownership in the company
- SEC Form 4: Gaeta Renee returned 36,056 shares to the company, closing all direct ownership in the company